Press Releases April 9, 2026 08:00 PM

Garrett Motion to Hold First Quarter 2026 Financial Results Conference Call on Thursday April 30, 2026

Garrett Motion schedules Q1 2026 financial results release and conference call for April 30, 2026.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
GTX

Garrett Motion Inc., a global leader in turbocharging and electrification technologies, announced it will release its first-quarter 2026 financial results on April 30, 2026, prior to U.S. market opening, followed by a conference call and webcast. The company highlights its ongoing commitment to innovation in automotive turbocharging, hydrogen fuel cell compressors, electric propulsion, and thermal management systems serving automotive and industrial sectors.

Garrett Motion to Hold First Quarter 2026 Financial Results Conference Call on Thursday April 30, 2026
GTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 financial results to be released on April 30, 2026, before market open.
  • Conference call scheduled same day with webcast and slide presentation for investor engagement.
  • Garrett Motion emphasizes its technology leadership in turbocharging and emerging electric and hydrogen fuel cell vehicle components.

PLYMOUTH, Mich. and ROLLE, Switzerland, April 10, 2026 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (Nasdaq: GTX), a global leader in differentiated turbocharging and electrification technologies, today announced that it will publish its first‑quarter financial results on Thursday, April 30, 2026, prior to the opening of the market trading in the United States.

Garrett will host a conference call that same day at 8:30 am EST / 2:30 pm CET. To participate in the conference call, please dial +1-877-883-0383 (U.S.) or +1-412-902-6506 (international) and use the passcode 3761849.

The conference call will also be webcast and will include a slide presentation. To access the webcast and supporting materials, please visit the Investor Relations section of the Garrett Motion website at https://investors.garrettmotion.com/. A replay of the conference call will be available by dialing +1-855-669-9658 (U.S.) or +1-412-317-0088 (international) and using access code 7390409. The webcast will also be archived on Garrett’s website.

About Garrett Motion Inc.
A differentiated technology leader, Garrett Motion has a 70-year history of innovation in the automotive sector (cars, trucks) and beyond (off-highway equipment, marine, power generators). Its well-recognized expertise in turbocharging has enabled significant reductions in engine size, fuel consumption, and CO2 emissions. Garrett is committed to advancing turbo applications while leveraging its unique technology solutions, such as fuel c ell compressors for hydrogen fuel cell vehicles, as well as electric propulsion and thermal management systems for automotive and industrial applications. Garrett has six R&D centers, 13 manufacturing facilities and a team of more than 8,700 employees in more than 20 countries. For more information, please visit www.garrettmotion.com.

Contacts:

INVESTOR RELATIONSMEDIACyril GrandjeanFabrice Spenninck+1 734 392 55 04 [email protected]@garrettmotion.com



Risks

  • Financial results may not meet market expectations, impacting stock price.
  • Ongoing automotive sector shifts towards electrification and hydrogen could affect demand or require significant R&D investment.
  • Global economic or supply chain challenges impacting manufacturing output or costs.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026